- Arens S., Schlegel U., Printzen G., Ziegler W. J., Perren S. M., Hansis M. Influence of materials for fixation implants on local infection. J Bone Joint Surg (Br) 1996; 78: 647–51
- Blaser J., Vergères P., Widmer A. F., Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of devicerelated infection. Antimicrob Agents Chemother 1995; 39(5)1134–9
- Cunha B. A. Intravenous to oral antibiotic switch therapy. Drugs Today (Barc.) 2001; 37(5)311–9
- Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43: 51–9, (Suppl B)
- Firsov A. A., Vostrov S. N., Lubenko I. Y., Drlica K., Portnoy Y. A., Zinner S. H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47(5)1604–13
- Garcia F., Lacleriga A., Monzon M., Leiva J., Oteiza C., Amorena B. Application of a rat osteomyelitis model to compare in vivo and in vitro antibiotic efficacy against bacteria with high capacity to form biofilms. J Surg Res 1998; 79: 146–53
- Hoogkamp-Korstanje J. A., Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000; 45(1)31–9
- Ince D., Zhang X., Hooper D. C. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47(4)1410–5
- Jones M. E., Visser M. R., Klootwijk M., Heisig P., Verhoef J., Schmitz F. J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999; 43(2)421–3
- Joukhadar C., Stass H., Muller-Zellenberg U., Lackner E., Kovar F., Minar E., Muller M. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003; 47(10)3099–103
- Kaarsemaker S., Walenkamp G., Vanderbogaard A. E. J. New model for chronic osteomyelitis with staphylococcus aureus in sheep. Clin Orthop 1997, 339: 246–52
- Kaatz G. W., Moudgal V. V., Seo S. M. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother 2002; 50(6)833–8
- Lister P. D. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001; 32: S33–S38, (Suppl 1)
- Mayberry-Carson K. J., Tober-Meyer B., Smith J. K., Lambe D. W., Costerton J. W. Bacterial adherence and glycocalix formation in osteomyelitis experimentally induced with Staphylococcus aureus. Infect Immun 1984; 43: 825–33
- Melcher G. A., Claudi B., Schlegel U., Perren S. M., Printzen G., Munzinger J. Influence of type of medullary nail on the development of local infection. J Bone Joint Surg (Br) 1994; 76: 955–9
- Monzon M., Garcia-Alvarez F., Lacleriga A., Amorena B. Evaluation of four experimental osteomyelitis infection models by using precolonized implants and bacterial suspensions. Acta Orthop Scand 2002; 73(1)11–9
- Müller M., Stass H., Brunner M., Moller J. G., Lackner E., Eichler H. G. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43(10)2345–9
- Pong A., Thomson K. S., Moland E. S., Chartrand S. A., Sanders C. C. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 1999; 44(5)621–7
- Rodvold K. A., Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21: 233S–52S
- Saleh-Mghir A., Ameur N., Muller-Serieys, Ismael F., Lemaitre F., Massias L., Feger C., Bléton R., Crémieux A. C. Combination of Quinupristin-Dalfopristin (Synercid) and Rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002; 46(4)1122–4
- Stass H., Kubitza D., Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxy-fluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40: 1–9, (Suppl 1)
- Zimmerli W., Widmer A. F., Blatter M., Frei R., Ochsner P. E. Role of rifampin for treatment of orthopaedic implantrelated Staphylococcus aureus: a randomized controlled trial. JAMA 1998; 279: 1537–41
Acta Orthopaedica
Volume 77, 2006 - Issue 2